Results 41 to 50 of about 801 (115)

Clinical potential of lurasidone in the management of schizophrenia

Therapeutics and Clinical Risk Management, 2011
Ludovic Samalin, Marion Garnier, Pierre-Michel LlorcaCentre Hospitalier Universitaire, Clermont-Ferrand, FranceAbstract: Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of
Samalin L, Garnier M, Llorca PM
doaj  

Antipsychotic prescribing patterns and determinants in first-episode psychosis: a 2019–2024 cross-sectional study from Zambia

BMC Psychiatry
Background First-episode psychosis represents a critical period in psychotic disorders, during which timely, appropriate treatment can greatly influence long-term outcomes.
Lihlizulu Thabo Moyo, Thandiwe Martha Tembo, Brian Maila   +2 more
doaj   +1 more source

Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study

Indian Journal of Psychiatry, 2018
Background: Metabolic syndrome in individuals taking second-generation antipsychotics is thought to be mediated by antipsychotic-induced weight gain. However, recent literature challenges this notion, and theoretically, it may also be mediated through ...
Rupali Rohatgi, Ravi Gupta, Rajat Ray, Vinita Kalra   +3 more
doaj   +1 more source

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

Patient Preference and Adherence, 2010
L Samalin, T Charpeaud, O Lorabi, PM LlorcaCentre Hospitalier Universitaire, Clermont-Ferrand, FranceAbstract: In the last few years, oral second-generation antipsychotics have demonstrated mood-stabilizing properties and are now widely used in the ...
L Samalin, T Charpeaud, O Lorabi, et al
doaj  

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

BMC Psychiatry, 2018
Background Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated.
Vasiliki Mamakou, Sophie Hackinger, Eleni Zengini, Evgenia Tsompanaki, Eirini Marouli, Ioannis Serafetinidis, Bram Prins, Athina Karabela, Eirini Glezou, Lorraine Southam, Nigel W. Rayner, Karoline Kuchenbaecker, Klea Lamnissou, Vassilis Kontaxakis, George Dedoussis, Fragiskos Gonidakis, Anastasia Thanopoulou, Nikolaos Tentolouris, Eleftheria Zeggini   +18 more
doaj   +1 more source

Second-generation antipsychotics and constipation: A review of the literature

European Psychiatry, 2011
AbstractAntipsychotics are the cornerstone in the management of psychotic disorders and schizophrenia. They are effective agents but also have a wide range of side effects. In the recent literature constipation as possible side effect has received little attention.
M, De Hert, H, Hudyana, L, Dockx, C, Bernagie, K, Sweers, J, Tack, S, Leucht, J, Peuskens   +7 more
openaire   +2 more sources

Clinical use of second-generation antipsychotics in children [PDF]

Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2017
Kirsi Kakko, Leena Pihlakoski, Raili Salmelin, Päivi Keskinen, Kaija Puura, Tuula Tamminen   +5 more
doaj   +1 more source

Clinical utility of the risperidone formulations in the management of schizophrenia

Neuropsychiatric Disease and Treatment, 2011
Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second ...
Madaan V, Bestha DP, Kolli VB, Jauhari S, Burket RC   +4 more
doaj  

Quetiapine-induced Stevens–Johnson syndrome: A rare case report

Telangana Journal of Psychiatry
Quetiapine, a second-generation antipsychotic drug, commonly has very less propensity of extrapyramidal symptoms and has an added advantage of less risk of serum prolactin, weight gain, or metabolic syndrome than other second-generation antipsychotics ...
Soumi Ghosh, Arijit Mondal, Sourav Bag, Abhijit Chattopadhyay   +3 more
doaj   +1 more source

Effectiveness of second generation antipsychotics: A systematic review of randomized trials

BMC Psychiatry, 2008
Background Systematic reviews based on efficacy trials are inconclusive about which second generation antipsychotic drug (SGA) should be preferred in normal clinical practice, and studies with longer duration and more pragmatic designs are called for ...
Jørgensen Hugo A, Johnsen Erik
doaj   +1 more source